ClinicalTrials.gg
Not yet recruitingNCT06703112Updated Nov 25, 2024

Establishment and Clinical Application of AI-based Multimodal Diagnosis System for Ovarian Tumors

An interventional study of An auxiliary diagnostic model for ovarian tumors in Ovarian Tumors, sponsored by Beijing Shijitan Hospital, Capital Medical University. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Beijing Shijitan Hospital, Capital Medical University · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
584
Allocation
Not applicable
Sex
Female
01

Study summary

Ovarian tumors are a common disease that threatens women's health. They are insidious in onset, have over ten pathological types, and exhibit diverse biological behaviors, making accurate diagnosis a key factor in clinical decision-making and improving prognosis. Introducing AI technology to establish an auxiliary diagnosis system composed of multi-dimensional clinical data, including medical imaging and tumor markers, will greatly enhance diagnosis efficiency by predicting the pathological types of common ovarian tumors.

Our research group has innovatively developed an AI-based ultrasound intelligent auxiliary diagnosis software for ovarian tumors, which has been clinically validated to be effective. This project will build on this by: (1) utilizing a wealth of multi-center retrospective clinical data to combine ultrasound, MRI images, physiological, pathological, and laboratory data to form the first multi-modal ovarian tumor public dataset supporting AI tasks; (2) using convolutional neural network technology to realize multi-modal image multi-classification intelligent recognition on this dataset based on surgical pathology as the standard, and then fuse features at the level of clinical data with the intelligent recognition model to train and validate an auxiliary diagnosis model for predicting the top ten pathological types of ovarian tumors; (3) applying privacy computing and federated learning methods to conduct multi-center, prospective validation and optimization of the above model, ultimately forming a clinical auxiliary diagnosis system that can predict the pathological types of most ovarian tumors and apply it to clinical practice.

Read the detailed description

Methods/Design Study Aim The first objective of this study are to construct a multimodal ovarian tumor public dataset that includes ultrasound, MRI images, and clinical indicator data to support AI-driven tasks. This dataset will integrate diverse types of medical data to facilitate comprehensive AI analysis and model training. By employing convolutional neural network (CNN) technology, the study seeks to achieve intelligent multiclass recognition of multimodal images. This involves extracting and analyzing features from imaging data and integrating them with multidimensional clinical data at the feature level, with the goal of training and validating an auxiliary diagnostic model capable of accurately predicting at least the ten most common pathological types of ovarian tumors. Additionally, the study will utilize privacy-preserving computing and federated learning methods to conduct multicenter, prospective optimization and validation of the model. These methods will ensure data security and privacy while enabling collaborative model training. The ultimate goal is to develop a clinical auxiliary diagnostic system that can predict the pathological types of most ovarian tumors and be implemented in clinical settings. This comprehensive approach aims to leverage the strengths of AI technology in medical imaging, ensuring data security while enhancing the accuracy and reliability of ovarian tumor diagnosis.

Study Setting This study is conducted in Beijing, China. The study subjects are sourced from Beijing Shijitan Hospital, Beijing Friendship Hospital, and Beijing Obstetrics and Gynecology Hospital, all of which are affiliated with Capital Medical University. These hospitals provide a diverse patient population, which supports the generalizability of the study findings.

Study Subjects The study subjects are patients diagnosed with ovarian tumors who have undergone surgical treatment. The cases used for developing the predictive model are sourced from patients who were consecutively enrolled between January 2018 and January 2023. Clinical application validation cases will be prospectively collected from patients between June 2023 and June 2025. The inclusion criteria for both parts of the study are as follows: (1) patients diagnosed with ovarian tumors who have undergone surgical treatment; (2) patients with complete imaging data (ultrasound or MRI) and tumor marker results obtained within three months prior to surgery. Additionally, the second part requires informed consent from the participants. The exclusion criteria are as follows: (1) patients with surgical pathology not originating from the ovary; (2) duplicate cases; (3) patients who have received chemotherapy or radiotherapy; (4) recurrent cases; (5) poor-quality imaging of ovarian lesions; and (6) incomplete case information.

Ethics The study protocol has been reviewed and approved by the Ethics Committee of Beijing Shijitan Hospital, affiliated with Capital Medical University. The ethics approval number is: [provide number]. The study will be conducted in accordance with the principles of the Declaration of Helsinki. For the model development phase, retrospective cases have been granted a waiver of informed consent. For the clinical validation phase, all participants will read an informed consent form before the study begins, voluntarily agree to participate, and sign the informed consent form.

Data Collection The investigators will collect imaging data (pelvic ultrasound, pelvic MRI) and clinical data (general information, medical history, family history, physical examination, laboratory tests, pathology reports, clinical diagnosis, etc.) from the study subjects. This will help construct a multimodal ovarian tumor dataset with classification and segmentation annotations, providing AI dataset support for the subsequent development of multimodal ovarian tumor auxiliary diagnostic models. As the research progresses, the investigators aim to achieve flexible expansion and deep mining of the dataset, establish standardized protocols for multimodal datasets, and enable effective data sharing.

Image Data Processing, Segmentation, and Classification Annotation This project utilizes the OpenSlide tool to process images, resizing them to ensure pixel dimensions are multiples of 300. The images are subsequently split into 300×300 pixel sections and converted to PNG format. Accurate segmentation of lesions is fundamental for precise image recognition. The project involves a team of gynecologists, as well as experts from the School of Electronic and Information Engineering at Beihang University, who use the professional annotation software LabelMe for image segmentation and classification annotation based on pathological results, thereby creating a segmented and classified database. For instance, in the case of 2D ultrasound images, the lesions are manually segmented, with ovarian tumor locations marked and converted into corresponding classification labels.

To further enhance segmentation accuracy and outcomes, this study constructs an ovarian tumor image segmentation network architecture, incorporating a multi-scale feature fusion module and multi-level loss function optimization. The overall network architecture combines superpixel segmentation with deep learning, leveraging the strong feature extraction capabilities of convolutional neural networks (CNN) to enhance edge information and improve segmentation accuracy.

Constructing an AI-based Ovarian Tumor Auxiliary Diagnosis System Utilizing AI for Image Recognition For the input multimodal images (ultrasound and MRI), visual feature extraction is performed. To address the visual tasks of lesion classification and segmentation, two algorithm models are constructed: a dense residual structure model and a multi-level edge-aware structure model. These models enable intelligent recognition of pathological types in multimodal images

Predictive Model Integrating Multidimensional Structured Data Firstly, convolutional neural networks are used to generate pixel-level prediction results (segmentation results) and AI algorithms provide AI prediction results (posterior probabilities). Subsequently, the posterior probability vector is feature-fused with structured data (age, chief complaint, duration of illness, physical examination findings, laboratory tests, and other clinical indicators). These are concatenated into a new feature vector, which is then further analyzed by a decision model (such as XGBoost) to determine the pathological category of the ovarian tumor. The model is trained and validated using pathological results as the gold standard.

Auxiliary Diagnosis System he multimodal ovarian tumor auxiliary diagnosis system is structured into several hierarchical levels. The system consists of four main levels, from bottom to top: 1)Underlying Module: This module is primarily responsible for providing deep learning inference acceleration, ensuring the foundational capabilities required for system operation. 2)Basic Application Library (Foundation Layer):This layer offers essential libraries for medical information processing and platform log recording. 3)Deep Learning Framework (Deep Learning Inference Layer):It serves as the intelligent core of the system, provides the foundational deep learning frameworks necessary for intelligent system inference. This includes commonly used neural network inference libraries that support precise neural network model inference across different platforms. 4)Application Layer (Subdivided into Application Layer and Component Layer):This layer offers the necessary services for the platform system. It is designed to be flexible and extensible, with independently functional, loosely coupled modules. The layers are relatively decoupled, with each providing independent functionality. The platform system is designed from the bottom up, featuring a user-friendly, externally encapsulated operational interface that allows direct user interaction with the platform.

The multimodal ovarian tumor auxiliary diagnosis system has several key functions. First, it can read ultrasound and MRI images, as well as medical records, according to user requirements, and convert the format as needed. It then preprocesses the images and medical records by removing irrelevant information, which facilitates subsequent model inference. The lesion recognition module performs both classification and segmentation, estimating lesion probabilities and identifying potential lesion areas. Finally, the data post-processing module conducts decision-level fusion of classification results, automatically annotates lesion areas, and generates auxiliary diagnostic results predicting pathological types by combining the medical record information.

Multicenter, Prospective Auxiliary Diagnosis System Optimization and Clinical Application Validation Through collaboration among gynecological oncology teams from three research centers, the multimodal ovarian tumor auxiliary diagnosis system will undergo multicenter, prospective clinical application, with surgical pathology results used as the gold standard. The diagnostic performance of the multimodal ovarian tumor auxiliary diagnosis system, both overall and across different pathological categories, will be evaluated in the main and subsidiary centers by comparing metrics such as specificity, sensitivity, positive predictive value, negative predictive value, and area under the ROC curve (AUC). The system will be continuously validated and optimized to improve its performance. The consistency between preoperative diagnosis and postoperative pathological results will be compared before and after the application of the ovarian tumor auxiliary diagnosis system in the three research centers, in order to evaluate the clinical effectiveness of the auxiliary diagnosis system.

Multicenter Auxiliary Diagnosis System Optimization Paradigm Based on Horizontal Federated Learning The multicenter auxiliary diagnosis system optimization paradigm based on horizontal federated learning involves the management and distribution of the auxiliary diagnosis model by the main center. Other centers apply incremental learning mechanisms, using their own data to fine-tune the auxiliary diagnosis system and provide updated parameters to the main center. This process ensures improved intelligent recognition of ovarian tumors while maintaining data privacy across centers. Initially, the main center constructs an AI-based multimodal ovarian tumor prediction model. This model is then encrypted and distributed to the branch centers. The branch centers, after reaching a certain data pool size and meeting annotation standards, initiate model optimization. Finally, after fine-tuning the models, each center uploads the updated parameters to the main center. The main center evaluates model performance to determine if a model version iteration is necessary. If so, the updated model is redistributed, achieving a closed-loop of horizontal federated learning for multicenter model optimization.

Statistical Analysis Sample size calculation

  1. Development Phase of the Multimodal Ovarian Tumor Auxiliary Diagnosis Model The sample size required is estimated using the EPV (Events per Variable) method, which is an experience-based method for constructing models. Each variable typically requires 10-20 positive events; in this study, the investigators set the EPV at 20. The investigators anticipate including 20 independent variables (and dummy variables) in the diagnostic model, thus needing 20 * 20 = 400 malignant cases. Preliminary data indicates that the proportion of malignant (true positive) ovarian tumor patients is approximately 30%. Therefore, the total required sample size is 400 / 0.30 = 1334 cases. Considering a 20% data loss rate, the final sample size for the training set is 1667 cases. The training set and validation set will follow a 4:1 ratio, resulting in a validation set sample size of 418 cases. Thus, the total sample size required is 2084 cases, with each center contributing an equal share.
  2. Multicenter, Prospective System Clinical Application Validation and Optimization Phase This part of the study primarily evaluates the clinical application effect of the auxiliary diagnosis system by measuring accuracy. Therefore, the sample size calculation formula for diagnostic tests is used.

Se=90% (Sensitivity of the diagnostic system),Sp=90% (Specificity of the diagnostic system), Based on statistical and clinical expert opinions, errABS=5% refers to the expected absolute error, α=0.05. According to the sample size calculation formula, the true positive group requires the inclusion of 140 cases. Preliminary data indicates that the proportion of malignant (true positive) ovarian tumor patients is approximately 30%. Therefore, the total required sample size is 140 / 0.30 = 467 cases. Considering a 20% loss to follow-up rate, the final sample size is 584 cases, with each center contributing an equal share.

Data Management All data will be registered in an electronic case report form (eCRF) designed for the study. Each sub-center will establish an independent database managed by designated personnel. A standardized data entry verification process will be established, ensuring that data is recorded accurately and timely in strict accordance with the study protocol. Regular evaluations will be conducted to check the accuracy and completeness of uploaded data. Data managers at each center will verify the data collected in the eCRFs against source documents such as medical records and review the data collection process. Staff from the main center will conduct periodic on-site inspections at all participating centers to verify the authenticity of the data. The study will employ privacy computing technology to ensure the independence and security of each center's data, providing services for multicenter model optimization and validation while ensuring data privacy.

Data Analysis For normally distributed continuous data, intergroup comparisons will be conducted using the independent samples t-test, and intragroup comparisons will be done using the paired t-test. For non-normally distributed continuous data and ordinal data, the Mann-Whitney U test will be used for intergroup comparisons, and the Wilcoxon signed-rank test will be used for intragroup comparisons. For unordered categorical data, the chi-square (χ²) test or Fisher's exact test will be used for intergroup comparisons, and the McNemar test will be used for intragroup comparisons.The area under the ROC curve (AUC) will be statistically tested using the DeLong test, and sensitivity and specificity will be calculated using the Jeffreys interval. Considering the correlation among the same subjects, intergroup comparisons will use the Generalized Estimation Equation (GEE) method adjusted for center effects. Analysis of other indicators will follow the same methodology as the baseline analysis.

02

Conditions studied

  • Ovarian Tumors

Browse trials for

Keywords

  • Ovarian Neoplasms
  • Artificial Intelligence
  • Multimodal Imaging
  • Computer-Assisted Diagnosis
  • Privacy Computing
03

In context

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

This study's planned enrollment of 584 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Beijing Shijitan Hospital, Capital Medical University is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Continuous cases admitted for diagnosis of ovarian tumor and preparation for surgical treatment;
    1. Complete imaging data (ultrasound or MRI) and tumor marker results within 3 months before surgery;
    1. Voluntarily sign .

Exclusion criteria

Exclusion Criteria:

    1. Patients with non-ovarian origin tumor as surgical pathology;
    1. Repetitive cases;
    1. Cases receiving radiotherapy and chemotherapy;
    1. Recurrent cases; 5. Poor image quality of ovarian lesions;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
584 participants (estimated)

Study arms

  • Active comparator
    ovarian tumors

    Diagnostic Test: An auxiliary diagnostic model for ovarian tumors

Interventions

  • Diagnostic testAn auxiliary diagnostic model for ovarian tumors

    Through collaboration among gynecological oncology teams from three research centers, the multimodal ovarian tumor auxiliary diagnosis system will undergo multicenter, prospective clinical application, with surgical pathology results used as the gold standard. The diagnostic performance of the multimodal ovarian tumor auxiliary diagnosis system, both overall and across different pathological categories, will be evaluated in the main and subsidiary centers by comparing metrics such as specificity, sensitivity, positive predictive value, negative predictive value, and area under the ROC curve (AUC).

06

What researchers measure

Primary outcomes

  1. Pathological diagnosis

    After the surgical specimen is delivered to the pathology department, the pathologist conducts a gross examination, recording the size, shape, surface characteristics, and cut surface features of the specimen (e.g., the proportion of solid and cystic components of the tumor). The specimen is then processed according to standard protocols to prepare tissue sections, which are subsequently stained. Once staining is complete, the slides are independently examined under a microscope by two pathologists, who evaluate the tumor cell morphology, arrangement, and histological characteristics to determine the pathological nature (benign, borderline, or malignant) and type of the tumor. If there is a discrepancy in the diagnoses, the case is referred to a senior pathologist for review, whose final opinion shall prevail.

    Time frame: Within one week postoperatively

  2. AUC (Area Under the ROC Curve)

    In this study, the area under the curve (AUC) is used as the primary evaluation metric to quantify the diagnostic performance of the new prediction model. AUC is based on the receiver operating characteristic (ROC) curve and evaluates the model's ability to distinguish between positive and negative cases at various thresholds by comparing the model's predictions with the gold standard (pathological diagnosis). Significance of AUC: The AUC value ranges from 0.5 to 1.0, with higher values indicating stronger overall discriminative ability of the model. Specific interpretations are as follows: AUC = 0.5: The model has no diagnostic capability. 0.7 ≤ AUC \< 0.9: The model demonstrates good diagnostic performance. AUC ≥ 0.9: The model shows excellent diagnostic performance. AUC \< 0.7: The model's diagnostic capability is considered low. By calculating the AUC value of the new prediction model, this study assesses its ability to distinguish positive cases from negative cases, thereby verif

    Time frame: All study subjects must complete follow-up within one year after postoperative pathological diagnosis.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2026, 18 months later.

Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 18 months is below that.

Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2024
First posted
Nov 25, 2024
StartEst.
Jun 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703112
Lead sponsor
Beijing Shijitan Hospital, Capital Medical University
Collaborators
Beijing Friendship Hospital, Beijing Obstetrics and Gynecology Hospital
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Jun 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 25, 2024

Study contacts

lei liu
Contact
cdcliulei@163.com
+86 13718692611

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion